Biologics Research Review, Issue 35 - Dermatology focus

In this issue:

Hidradenitis suppurativa ‘window of opportunity’ with adalimumab
Switching biologics for psoriasis
IL-6 and TNF-α relationship with cancer patients
Dupilumab, conjunctivitis and serious infection in atopic dermatitis
Drug survival of dupilumab vs cyclosporin for atopic dermatitis
Omalizumab for cholinergic urticaria
Reduced doses of biological therapies in psoriasis
Adalimumab for moderate-tosevere hidradenitis suppurativa
Psoriatic patient-based survey on vaccine understanding
DLQI in Japanese patients with plaque psoriasis

Please login below to download this issue (PDF)

Subscribe